William G Wierda

William G Wierda

UNVERIFIED PROFILE

Are you William G Wierda?   Register this Author

Register author
William G Wierda

William G Wierda

Publications by authors named "William G Wierda"

Are you William G Wierda?   Register this Author

100Publications

4130Reads

20Profile Views

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.

Br J Haematol 2019 Oct 25;187(1):e1-e4. Epub 2019 Jul 25.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16117DOI Listing
October 2019

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Cancer Cell 2019 Oct 19;36(4):369-384.e13. Epub 2019 Sep 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.08.005DOI Listing
October 2019

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know.

Ann Emerg Med 2019 Sep 24. Epub 2019 Sep 24.

Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annemergmed.2019.07.015DOI Listing
September 2019

Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Drugs 2019 Aug;79(12):1287-1304

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01163-4DOI Listing
August 2019

Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.

Leukemia 2019 07 30;33(7):1663-1674. Epub 2019 Jan 30.

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0364-xDOI Listing
July 2019

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.

Leuk Lymphoma 2019 Jun 4:1-4. Epub 2019 Jun 4.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1622098DOI Listing
June 2019

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Oncotarget 2019 Apr 19;10(29):2793-2809. Epub 2019 Apr 19.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497463PMC
April 2019

Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?

Authors:
William G Wierda

Clin Adv Hematol Oncol 2019 Apr;17(4):214-216

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
April 2019

Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy.

Neurology 2018 10;91(18):843

From the Departments of Diagnostic Imaging (N.G.-T.) and Leukemia (W.G.W.), MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006436DOI Listing
October 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.

Leuk Lymphoma 2018 06 3;59(6):1427-1438. Epub 2017 Oct 3.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1376747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882591PMC
June 2018

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.

Oncotarget 2018 May 18;9(38):24980-24991. Epub 2018 May 18.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/25166
Publisher Site
http://dx.doi.org/10.18632/oncotarget.25166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982765PMC
May 2018

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

Br J Haematol 2018 02 21;180(4):597-600. Epub 2016 Oct 21.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14398DOI Listing
February 2018

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Mol Cancer Res 2017 12 23;15(12):1692-1703. Epub 2017 Aug 23.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-17-0026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714317PMC
December 2017

Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.

Br J Haematol 2017 10 24;179(2):266-271. Epub 2017 Jul 24.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638689PMC
October 2017

The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.

Neoplasia 2017 Oct 30;19(10):762-771. Epub 2017 Aug 30.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, 1515 Holcombe Blvd., Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.07.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577399PMC
October 2017

PET-positive lymphadenopathy in CLL-Not always Richter transformation.

Am J Hematol 2017 04 7;92(4):405-406. Epub 2017 Feb 7.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352509PMC
April 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455685PMC
March 2017

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.

Oncotarget 2017 Mar;8(10):16259-16274

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369961PMC
March 2017

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Leuk Lymphoma 2016 16;57(6):1494-7. Epub 2015 Nov 16.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1102243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963009PMC
January 2017

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

J Clin Oncol 2017 Jan 21;35(2):166-174. Epub 2016 Nov 21.

Qiushi Chen and Turgay Ayer, Georgia Institute of Technology; Christopher R. Flowers, Emory University, Atlanta, GA; Qiushi Chen and Jagpreet Chhatwal, Massachusetts General Hospital; Jagpreet Chhatwal, Harvard Medical School, Boston, MA; Nitin Jain, William G. Wierda, Michael J. Keating, and Hagop M. Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, TX; and Susan M. O'Brien, University of California Irvine Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2856DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559889PMC
January 2017

Chronic lymphocytic leukaemia.

Nat Rev Dis Primers 2017 01 19;3:16096. Epub 2017 Jan 19.

CLL Research and Treatment Program, Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrdp201696
Publisher Site
http://dx.doi.org/10.1038/nrdp.2016.96DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336551PMC
January 2017

Minimal Residual Disease Provides Treatment Focus for Next Chronic Lymphocytic Leukemia Advances.

Authors:
William G Wierda

J Clin Oncol 2016 11;34(31):3722-3723

William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.1972DOI Listing
November 2016

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.

Clin Cancer Res 2016 Sep 29;22(18):4712-26. Epub 2016 Mar 29.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118040PMC
September 2016

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J Natl Compr Canc Netw 2016 09;14(9):1067-79

From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0117DOI Listing
September 2016

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.

Oncotarget 2016 Jun;7(26):39458-39472

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129945PMC
June 2016

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.

PLoS One 2015 1;10(6):e0128151. Epub 2015 Jun 1.

Pediatrics, Children's Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128151PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451012PMC
April 2016

Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells.

Leuk Lymphoma 2016 Feb 28;57(2):436-444. Epub 2015 Sep 28.

a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1063141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814351PMC
February 2016

Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Blood 2016 Jan 17;127(3):279-86. Epub 2015 Nov 17.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-634816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828075PMC
January 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
January 2016

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 7;374(4):323-32. Epub 2015 Dec 7.

From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586PMC
January 2016

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Cancer 2015 Nov 28;121(21):3869-76. Epub 2015 Jul 28.

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824541PMC
November 2015

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Clin Cancer Res 2015 Aug 31;21(16):3705-15. Epub 2015 Mar 31.

Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas. Department of Leukemia, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537801PMC
August 2015

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Clin Lymphoma Myeloma Leuk 2015 Jul 11;15(7):420-7. Epub 2015 Feb 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874253PMC
July 2015

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Clin Lymphoma Myeloma Leuk 2015 Jul 19;15(7):385-91. Epub 2015 Feb 19.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905707PMC
July 2015

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

EBioMedicine 2015 Jun 29;2(6):572-82. Epub 2015 Apr 29.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-1402, USA ; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.04.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535165PMC
June 2015

Updates to the management of chronic lymphocytic leukemia.

Authors:
William G Wierda

J Natl Compr Canc Netw 2015 May;13(5 Suppl):662-5

Presented by William G. Wierda, MD, PhD, Professor and Center Medical Director in the Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/13/5S/662.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2015.0197DOI Listing
May 2015